Success Stories: EB-1A Approved for Associate Research Scientist in Connecticut in the Field of Immunology
Client’s Testimonial:
Your clear strategy and wise approach have helped me out to get the I-140 approval in short time.Thanks!!!
On January 6, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for an Associate Research Scientist in the Field of Molecular & Cellular Immunology (Approval Notice)
Position at the Time of Case Filing: Associate Research Scientist
Country of Origin: India
Service Center: Texas Service Center (TSC)
Country of Residence at the Time of Filing: Connecticut
Approval Notice Date: January 6th, 2015
Processing Time: 27 Days (15 Days After Premium Processing Requested)
In this case, the client that we had the opportunity to work with was an Associate Research Scientist from India who had conducted his research with a highly specialized focus on the mechanisms of inflammatory and immune response. His work had resulted in 8 peer-reviewed scientific articles and numerous presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 265 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed at least 8 manuscripts for 4 distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from an independent recommender: “I highlighted [Client’s] work outlining the role of VAMP proteins in degranulation by SNARE molecules, as well as showing normal cytokine release in VAMP-8 deficient mice. These are incredibly novel findings that help elucidate which molecular pathways are involved in the release of newly synthesized cytokines.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Molecular and Cellular Immunology, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in twenty-seven days.